Stakeholders' Perspectives on Current Issues in Data Monitoring Committees
ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are wi...
Saved in:
Published in | Biometrical journal Vol. 66; no. 7; pp. e202300384 - n/a |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley - VCH Verlag GmbH & Co. KGaA
01.10.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 0323-3847 1521-4036 1521-4036 |
DOI | 10.1002/bimj.202300384 |
Cover
Abstract | ABSTRACT
Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC—We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions—We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data—We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays—We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality. |
---|---|
AbstractList | Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality. ABSTRACT Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC—We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions—We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data—We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays—We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality. Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality.Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor regarding the continuing safety of study subjects along with the continuing validity and scientific merit of the study. Although DMCs are widely used, considerable variability exists in their conduct. This paper offers recommendations, derived from sessions given at the 2023 Central European Network International Biometric and Statisticians in the Pharmaceutical Industry Conferences' and the authors' experiences. We focus on four topics that are part of the DMC process and where there is unclarity and inconsistency in current practices: (1) Communication with the DMC-We reflect on the importance of effective, proper communication channels between the DMC and relevant stakeholders to foster collaboration and exchange of critical information while retaining study integrity throughout. (2) Open sessions-We discuss the benefits of incorporating open sessions in DMC meetings to enhance transparency, inclusivity, and the consideration of diverse perspectives, as well as pitfalls of open sessions. (3) Access to efficacy data-We highlight the need for appropriate access to efficacy data by DMCs and discuss how to implement this in practice and how to address potential concerns regarding multiplicity. (4) Interactive data displays-We outline the utilization of interactive data displays to facilitate a more intuitive understanding of study results by the DMC. By addressing these topics, we aim to provide comprehensive practical recommendations that bridge the gap between current practices and optimal DMC functionality. |
Author | Cartwright, Michael J. Friede, Tim Roes, Kit Mütze, Tobias Lawrence, David May, Emma |
Author_xml | – sequence: 1 givenname: Michael J. orcidid: 0009-0008-2765-1571 surname: Cartwright fullname: Cartwright, Michael J. email: michael.cartwright@parexel.com organization: Parexel International Ltd – sequence: 2 givenname: Tim orcidid: 0000-0001-5347-7441 surname: Friede fullname: Friede, Tim organization: DZHK (German Center for Cardiovascular Research) – sequence: 3 givenname: David surname: Lawrence fullname: Lawrence, David organization: Novartis Pharma AG – sequence: 4 givenname: Emma surname: May fullname: May, Emma organization: BioNTech SE – sequence: 5 givenname: Tobias orcidid: 0000-0002-4111-1941 surname: Mütze fullname: Mütze, Tobias organization: Novartis Pharma AG – sequence: 6 givenname: Kit orcidid: 0000-0002-6775-1963 surname: Roes fullname: Roes, Kit organization: Radboud University Medical Center |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39308116$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1PGzEQhi2UigTKlSNaqQe4bBh_xLs-tgHaREFUajlb3l0vOOzaqe0F8e8xChQJCXGZkUbPMxrNu4dG1lmN0CGGKQYgp5Xp11MChALQku2gCZ4RnDOgfIQmQAnN07gYo70Q1gAggJFdNKaCQokxn6Dln6ju9K3rGu3DcfY71Y2uo7nXIXM2mw_eaxuzRQhDmhibnamosktnTXTe2Jts7vrexKh1-Iq-tKoL-uCl76Pri_O_81_56urnYv59ldcMU5Y3uCVMCD3jApQqcFuUVcs4UbrkuCkwrcqihrbiomFckUoo1paiojWjQnDO6D462e7dePcvXRVlb0Ktu05Z7YYgKYaSlqKY8YR-e4eu3eBtui5RmBczUVCcqKMXaqh63ciNN73yj_L1SwlgW6D2LgSvW1mbqKJxNnplOolBPochn8OQ_8NI2vSd9rr5Q0FshQfT6cdPaPljcbl8c58AtTeasA |
CitedBy_id | crossref_primary_10_1007_s43441_024_00720_8 |
Cites_doi | 10.1007/s43441‐023‐00499‐0 10.1056/NEJMra1510066 10.1177/1740774518764855 10.1177/2168479018754846 10.3310/hta9070 10.1177/1740774518764449 10.1201/9781315181608 10.1177/1740774516688915 10.1016/j.cct.2020.106154 10.1177/2168479017739268 10.1177/1740774517707743 10.1056/NEJMsb1601674 10.7326/M19‐1491 10.1002/0470854162 10.1002/sim.1791 10.1109/VL.1996.545291 10.1001/jama.2016.16070 10.1080/19466315.2020.1736142 10.1056/evidctw2200220 10.1056/evidctw2100005 10.1080/10543406.2014.925719 10.1186/s13063‐023‐07290‐4 |
ContentType | Journal Article |
Copyright | 2024 Wiley‐VCH GmbH. |
Copyright_xml | – notice: 2024 Wiley‐VCH GmbH. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 8FD FR3 K9. P64 7X8 |
DOI | 10.1002/bimj.202300384 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1521-4036 |
EndPage | n/a |
ExternalDocumentID | 39308116 10_1002_bimj_202300384 BIMJ202300384 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23N 3-9 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACIWK ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 DUUFO EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M67 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ O66 O9- OIG P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TN5 UB1 V2E VH1 W8V W99 WBKPD WIB WIH WIK WJL WOHZO WQJ WRC WUP WWH WXSBR WYISQ XBAML XG1 XPP XV2 Y6R YHZ ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG AMVHM CITATION CGR CUY CVF ECM EIF NPM 7QO 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 K9. P64 7X8 |
ID | FETCH-LOGICAL-c4134-d1f2499e5690aa71f78bf462ae861d713b87c0fb69d46a2b9a4f89b3c43996643 |
IEDL.DBID | DR2 |
ISSN | 0323-3847 1521-4036 |
IngestDate | Thu Jul 10 22:23:15 EDT 2025 Fri Jul 25 19:18:57 EDT 2025 Thu Apr 03 07:07:08 EDT 2025 Thu Apr 24 23:05:26 EDT 2025 Tue Jul 01 04:18:08 EDT 2025 Wed Jan 22 17:15:50 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | benefit‐risk patient safety data monitoring committee study integrity |
Language | English |
License | 2024 Wiley‐VCH GmbH. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4134-d1f2499e5690aa71f78bf462ae861d713b87c0fb69d46a2b9a4f89b3c43996643 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0002-6775-1963 0009-0008-2765-1571 0000-0002-4111-1941 0000-0001-5347-7441 |
OpenAccessLink | https://resolver.sub.uni-goettingen.de/purl?gro-2/145835 |
PMID | 39308116 |
PQID | 3116759731 |
PQPubID | 105592 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_3108389756 proquest_journals_3116759731 pubmed_primary_39308116 crossref_citationtrail_10_1002_bimj_202300384 crossref_primary_10_1002_bimj_202300384 wiley_primary_10_1002_bimj_202300384_BIMJ202300384 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2024 2024-10-00 2024-Oct 20241001 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | Biometrical journal |
PublicationTitleAlternate | Biom J |
PublicationYear | 2024 |
Publisher | Wiley - VCH Verlag GmbH & Co. KGaA |
Publisher_xml | – name: Wiley - VCH Verlag GmbH & Co. KGaA |
References | 2021; 13 2023; 57 2023; 24 2017; 14 2020 2016; 316 2005; 9 2004; 23 2020; 172 2016; 375 1996 2006 2014; 24 2016; 374 2018; 52 2016 2005 2022; 1 2023; 2 2002 2020; 98 2013 2024 2018; 15 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
References_xml | – volume: 24 start-page: 289 issue: 1 year: 2023 article-title: DMC Reports in the 21st Century: Towards Better Tools for Decision‐Making publication-title: Trials – volume: 24 start-page: 968 issue: 5 year: 2014 end-page: 975 article-title: Enhancing Trial Integrity by Protecting the Independence of Data publication-title: Journal of Biopharmaceutical Statistics – volume: 172 start-page: 119 issue: 2 year: 2020 end-page: 125 article-title: Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job publication-title: Annals of Internal Medicine – volume: 15 start-page: 321 issue: 4 year: 2018 end-page: 328 article-title: Data Monitoring Committees: Current Issues publication-title: Clinical Trials – volume: 98 year: 2020 article-title: Data Monitoring Committees for Clinical Trials Evaluating Treatments of COVID‐19 publication-title: Contemporary Clinical Trials – year: 2005 – volume: 57 start-page: 515 issue: 3 year: 2023 end-page: 520 article-title: Challenges in Implementing Futility Schemes, With Reference to Aducanumab publication-title: Therapeutic Innovation & Regulatory Science – volume: 9 start-page: 1 issue: 7 year: 2005 end-page: 238 article-title: Issues in Data Monitoring and Interim Analysis of Trials publication-title: Health Technology Assessment – year: 2024 – volume: 316 start-page: 2359 issue: 22 year: 2016 end-page: 2360 article-title: Enhancing the Scientific Integrity and Safety of Clinical Trials publication-title: JAMA – volume: 52 start-page: 459 issue: 4 year: 2018 end-page: 468 article-title: Reports to Independent Data Monitoring Committees publication-title: Therapeutic Innovation & Regulatory Science – volume: 13 start-page: 355 issue: 3 year: 2021 end-page: 366 article-title: Clinical Trial Drug Safety Assessment With Interactive Visual Analytics publication-title: Statistics in Biopharmaceutical Research – year: 2016 – start-page: 336 year: 1996 end-page: 343 article-title: The Eyes Have It: A Task by Data Type Taxonomy of Information Visualizations – volume: 374 start-page: 1580 issue: 16 year: 2016 end-page: 1584 article-title: Challenges to Data Monitoring Committees When Regulatory Authorities Intervene publication-title: The New England Journal of Medicine – volume: 375 start-page: 1365 issue: 14 year: 2016 end-page: 1371 article-title: Data Monitoring Committees—Expect the Unexpected publication-title: New England Journal of Medicine – volume: 14 start-page: 115 issue: 2 year: 2017 end-page: 123 article-title: Data Monitoring Committees: Promoting Best Practices to Address Emerging Challenges publication-title: Clinical Trials: Journal of the Society for Clinical Trials – year: 2002 – year: 2006 – year: 2020 – volume: 2 issue: 2 year: 2023 article-title: The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials publication-title: NEJM Evidence – volume: 1 issue: 1 year: 2022 article-title: Independent Oversight of Clinical Trials Through Data and Safety Monitoring Boards publication-title: NEJM Evidence – volume: 52 start-page: 696 issue: 6 year: 2018 end-page: 700 article-title: The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials publication-title: Therapeutic Innovation & Regulatory Science – volume: 23 start-page: 1535 issue: 10 year: 2004 end-page: 1539 article-title: A Major Trial Needs Three Statisticians: Why, How and Who? publication-title: Statistics in Medicine – volume: 14 start-page: 342 issue: 4 year: 2017 end-page: 348 article-title: Recommendations for Data Monitoring Committees From the Clinical Trials Transformation Initiative publication-title: Clinical Trials – volume: 15 start-page: 359 issue: 4 year: 2018 end-page: 365 article-title: How to Construct an Optimal Interim Report: What the Data Monitoring Committee Does and Doesn't Need to Know publication-title: Clinical Trials – year: 2013 – ident: e_1_2_10_14_1 doi: 10.1007/s43441‐023‐00499‐0 – ident: e_1_2_10_4_1 doi: 10.1056/NEJMra1510066 – ident: e_1_2_10_12_1 doi: 10.1177/1740774518764855 – ident: e_1_2_10_29_1 doi: 10.1177/2168479018754846 – ident: e_1_2_10_15_1 doi: 10.3310/hta9070 – ident: e_1_2_10_19_1 doi: 10.1177/1740774518764449 – ident: e_1_2_10_24_1 – ident: e_1_2_10_16_1 doi: 10.1201/9781315181608 – ident: e_1_2_10_11_1 doi: 10.1177/1740774516688915 – ident: e_1_2_10_18_1 doi: 10.1016/j.cct.2020.106154 – ident: e_1_2_10_2_1 doi: 10.1177/2168479017739268 – ident: e_1_2_10_26_1 – ident: e_1_2_10_3_1 doi: 10.1177/1740774517707743 – ident: e_1_2_10_20_1 – ident: e_1_2_10_23_1 doi: 10.1056/NEJMsb1601674 – ident: e_1_2_10_9_1 doi: 10.7326/M19‐1491 – ident: e_1_2_10_5_1 doi: 10.1002/0470854162 – ident: e_1_2_10_21_1 doi: 10.1002/sim.1791 – ident: e_1_2_10_22_1 doi: 10.1109/VL.1996.545291 – ident: e_1_2_10_17_1 doi: 10.1001/jama.2016.16070 – ident: e_1_2_10_28_1 doi: 10.1080/19466315.2020.1736142 – ident: e_1_2_10_10_1 doi: 10.1056/evidctw2200220 – ident: e_1_2_10_7_1 – ident: e_1_2_10_25_1 – ident: e_1_2_10_6_1 – ident: e_1_2_10_8_1 doi: 10.1056/evidctw2100005 – ident: e_1_2_10_13_1 doi: 10.1080/10543406.2014.925719 – ident: e_1_2_10_27_1 doi: 10.1186/s13063‐023‐07290‐4 |
SSID | ssj0009042 |
Score | 2.3721304 |
SecondaryResourceType | review_article |
Snippet | ABSTRACT
Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor... Data Monitoring Committees (DMCs) are groups of experts that review accumulating data from one or more ongoing clinical studies and advise the Sponsor... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e202300384 |
SubjectTerms | benefit‐risk Biometry - methods Clinical Trials Data Monitoring Committees data monitoring committee Displays Effectiveness Humans Monitoring patient safety Pharmaceutical industry Scientific validity Stakeholder Participation study integrity |
Title | Stakeholders' Perspectives on Current Issues in Data Monitoring Committees |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbimj.202300384 https://www.ncbi.nlm.nih.gov/pubmed/39308116 https://www.proquest.com/docview/3116759731 https://www.proquest.com/docview/3108389756 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA8yEHzx-2M6JYKwp25rmn7kUZ1DBxMRB3srSZvCnHbiugf9671r2s4pIuhbSy40zeWS3-WS3xFyFuhExZENvkkCauCxBJsLfGZ5knHFY-0mGu8OD2696yHvj9zRp1v8hh-i2nBDy8jnazRwqWbtBWmoGj8_tjD5Nwa3kBDUdjwkz-_eL_ijRIebMAJzLBDyS9bGDmsvV19elb5BzWXkmi89vQ0iy0abEyeT1jxTrej9C5_jf_5qk6wXuJSem4G0RVZ0uk1WTabKtx3SB1A60RiqArjYpHeLK5ozOk1pwfJETS4_Ok5pV2aSmgkDdw4pXkQZZ5nWs10y7F09XF5bRRoGK4IVjluxnYCPJrQLjrSUvp34gUq4x6QOPDsGJ1cFftRJlCdiDipWQoLehXIidHU8QDx7pJZOU31AKHekjF03igItuHK09HGSYzpIXCaYUnVilWoIo4KjHFNlPIWGXZmF2D9h1T910qzkXww7x4-SjVKrYWGls9DBIJSLybvq5LQqBvvCoIlM9XSOMgBSA-G7Xp3sm9FQfcoRDiAqG0pYrtNf2hBe3Az61dvhXyodkTV45uY0YYPUste5PgZUlKmTfOR_AOEUAlk |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT-MwEB6xILRceC5QnkZaiVPaxnEePvJUKRShFUh7i-zEkcojRTQ9wK9npk5SFYRWWo6Jx4rj8djfeOxvAH5HJtNp4qJvkqEaRKrQ5qKQO4HiQovU-Jmhu8O966BzJ7p__eo0Id2FsfwQ9YYbWcZ4viYDpw3p1oQ1VPef7puU_ZuiW-IHzAlEG-R_nf6ZMEjJtrCBBO45KBVWvI1t3pquP70ufQKb09h1vPicL4Gumm3PnDw0R4VuJm8fGB2_9V_LsFhCU3Zkx9IKzJh8FeZtssrXNegiLn0wFK1CxHjIbia3NIdskLOS6InZdH6sn7NTVShm5wzaPGR0F6VfFMYMf8Hd-dntSccpMzE4CS5ywkndDN00aXz0pZUK3SyMdCYCrkwUuCn6uToKk3amA5kK1LKWClUvtZeQtxMg6FmH2XyQm01gwlMq9f0kiYwU2jMqpHmOmyjzueRaN8Cp9BAnJU05Zct4jC3BMo-pf-K6fxpwWMs_W4KOLyV3KrXGpaEOY4_iUD7l72rAQV2MJkZxE5WbwYhkEKdGMvSDBmzY4VB_ypMegioXS_hYqf9oQ3x80evWT1v_U2kffnZue1fx1cX15TYs4HthDxfuwGzxMjK7CJIKvTc2g3ca6wZ4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED9BEYgX2Pjs6DZPmsRT2sZxPvwIYxV0AyEEEm-RndhS-UgRTR_gr99dnabr0IQEj4nPiuPz2b_z2b8D-J4Yq_PMR9_EohpErtDmkph7keJCi9yE1tDd4dOz6PhK9K_D679u8Tt-iHrDjSxjMl-TgT_ktjMjDdWD-5s2Jf-m4JZYhCURIZwgWHQxI5CSXeHiCDzwUCqe0jZ2eWe-_vyy9AJrzkPXydrTWwc1bbU7cnLbHpe6nT3_Q-j4nt_6AGsVMGUHbiR9hAVTbMCyS1X5tAl9RKW3hmJViBf32fnsjuaIDQtW0Twxl8yPDQp2pErF3IxBW4eMbqIMytKY0RZc9X5e_jj2qjwMXoZLnPBy36KTJk2InrRSsW_jRFsRcWWSyM_Ry9VJnHWtjmQuUMdaKlS81EFGvk6EkGcbGsWwMLvARKBUHoZZlhgpdGBUTLMcN4kNueRaN8GbqiHNKpJyypVxlzp6ZZ5S_6R1_zRhv5Z_cPQc_5VsTbWaVmY6SgOKQoWUvasJ3-piNDCKmqjCDMckg8MqkXEYNWHHjYb6U4EMEFL5WMInOn2lDenhyWm_fvr0lkpfYeX8qJf-Pjn7tQer-Fq4k4UtaJSPY_MZEVKpv0yM4A_4MgUn |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stakeholders%27+Perspectives+on+Current+Issues+in+Data+Monitoring+Committees&rft.jtitle=Biometrical+journal&rft.au=Cartwright%2C+Michael+J.&rft.au=Friede%2C+Tim&rft.au=Lawrence%2C+David&rft.au=May%2C+Emma&rft.date=2024-10-01&rft.issn=0323-3847&rft.eissn=1521-4036&rft.volume=66&rft.issue=7&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fbimj.202300384&rft.externalDBID=10.1002%252Fbimj.202300384&rft.externalDocID=BIMJ202300384 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0323-3847&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0323-3847&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0323-3847&client=summon |